Oncology Nurse Advisor was launched in May 2010, and our readership since then continues to grow as we provide a mix of news, features, and perspective articles on topics of interest to oncology nurses and other clinicians in the cancer care continuum.

As part of our 10-year anniversary celebration, the editors present the following list of the 10 most popular articles that were published on Oncology Nurse Advisor over the past decade.

10. Nurse-Led Intervention Attempts to Address Posttreatment Needs of Lymphoma Survivors [August 15, 2019] Routine treatment following lymphoma therapy can fail to address the supportive care needs of lymphoma survivors. This randomized, controlled trial compared the efficacy of a nurse-led intervention consisting of 3 in-person appointments, an individually customized survivorship care plan and treatment summary, and delivery of personalized resources with usual care.

9. Does Adhering to the Mediterranean Diet Lower the Risk of Skin Cancer? [August 8, 2019] Given its disease-reducing capability, a team of researchers from France, Belgium, and Greece set out to determine whether the Mediterranean diet — which consists largely of plant-based and nutrient-rich foods including fruits, vegetables, nuts, whole grains, and olive oil — might also lower the risk of skin cancer.


Continue Reading

8. Managing TSH Levels After Total Thyroidectomy [September 8, 2015] An Advisor Forum panelist explains how to manage treatment so thyroid-stimulating hormone (TSH) levels are maintained within the normal range in patients who underwent total thyroidectomy for cancer of the papillary thyroid, as well as how to manage dosage adjustments for high-risk patients.

7. Nurses’ Guide to Managing Symptoms of Myeloproliferative Neoplasms [July 25, 2019] A guide to the best approaches for managing symptoms associated with the most common BCR-ABL1-negative myeloproliferative neoplasms (MPNs) is presented, including specific drugs, symptoms, and overall treatment strategies.

6. Ibrutinib Therapy Linked to New, Worsened Hypertension [October 22, 2019] In a study of 562 patients with B-cell malignancies, researchers examined the incidence of new/incident or worsened hypertension. Findings showed that more than 75% of patients developed new or worsened hypertension following treatment with ibrutinib. In addition, multivariate analysis associated development of major adverse cardiovascular events (MACE) with ibrutinib use.

5. Childhood Cancer Treatment Increases Risk for Breast Cancer Later [November 5, 2019] Investigators at the US National Cancer Institute in Bethesda, Maryland, evaluated the risk of breast cancer among survivors of childhood cancers who were treated with radiotherapy and chemotherapy. Data from 5-year survivors indicated rates of subsequent breast cancer were higher for this cohort.

4. Delay of Surgery for DCIS Ups Risk for Invasive Breast Cancer [November 4, 2019] Does an increased delay between diagnosis and surgery for ductal carcinoma in situ (DCIS) have a correlation to worse patient survival or greater risk for invasive disease? Researchers at the Naval Medical Center in Portsmouth, Virginia, report on the effect of delayed surgery on overall survival (OS) and presence of invasive disease in a study of 140,615 patients with clinical DCIS.

3. High Fiber, Yogurt Intake Linked to Reduced Risk for Lung Cancer [November 4, 2019] Results of this study demonstrated that dietary fiber and yogurt intakes were inversely associated with lung cancer risk. This pooled analysis of 10 prospective cohort studies involved a total of 1,445,850 adults.

2. Large-Volume IM Injections: A Review of Best Practices [February 22, 2013] This widely shared article examines the practical issues related to large-volume intramuscular (IM) injections with a focus on best practices for efficacy and safety, discussed within the setting of administering fulvestrant in the treatment of breast cancer. The article reviews the benefits of this administration method and illustrates the 5 potential sites for IM injection.

1. Weighing Benefits, Risks of Antenatal Chemotherapy in Pregnant Women With Hodgkin Lymphoma [October 18, 2019] This retrospective cohort study set out to evaluate the clinical outcomes for both mother and child when the patient was treated with antenatal chemotherapy compared with those who were not treated. Both neonatal and obstetric outcomes were measured, including rates of admission to the neonatal intensive care unit, neonatal birth weight, likeliness of preterm contractions, and premature rupture of membranes. Overall survival (OS) rates for pregnant and matched nonpregnant patients treated with chemotherapy were also compared.